
-
Verastem Oncology NasdaqCM:VSTM Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Location: 117 Kendrick Street, Needham, MA, 02494, United States | Website: https://www.verastem.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
386.2M
Cash
117.6M
Avg Qtr Burn
-28.79M
Short % of Float
31.17%
Insider Ownership
0.70%
Institutional Own.
78.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COPIKTRA (duvelisib) Details Chronic lymphocytic leukemia, Small lymphocytic lymphoma , Cancer, Follicular lymphoma | Approved Quarterly sales | |
Avutometinib (VS-6766) +/- Defactinib (AVMAPKI FAKZYNJA CO-PACK) Details Ovarian cancer, Cancer, Low-Grade Serous Ovarian Cancer | Approved Quarterly sales | |
Avutometinib (VS-6766) + LUMAKRAS (sotorasib) Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Avutometinib (VS-6766), + defactinib+gemcitabine/nab-paclitaxel Details First-Line Metastatic Pancreatic Cancer | Phase 1/2 Data readout | |
GFH375 (VS-7375) Details Cancer | Phase 1/2 Initiation | |
Avutometinib(VS-6766) (RAF/MEK Inhibitor) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
Avutometinib (VS-6766) + KRAZATI (adagrasib) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |